300+ investors in your industry, stage, and region Get
Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Financial Services
Construction
Mobile
Oil and Gas
Retail
Payments
Film
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Social Network
B2B
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Theatre
Beauty
Fashion
Infrastructure
Social
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Medical
Wine and Spirits
Mobile Apps
Real Estate
Web3
Sporting Goods
Music
Art
Finance
Recruiting
Manufacturing
FinTech
Franchise
Social Media
Internet
Mobile Advertising
Android
Impact
Enterprise
Proptech
Hardware
Transportation
Community
Biotech
Sustainability
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
Faroe Islands
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
South Korea
Oman
Puerto Rico
Poland
Guernsey
Cameroon
China
Colombia
Armenia
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Morocco
Australia
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Moldova
New Zealand
Seychelles
Paraguay
Botswana
France
South Africa
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Ron Doornink, Angel Investor

Ron Doornink

Angel Investor

Los Angeles, United States

Ron Doornink is a Series A investor in Los Angeles focused on Video and Computer. Ron is an Operating Partner with Stripes Group, primarily focused on evaluating and supporting branded consumer products and consumer technology businesses.Ron currently serves as chairman of Turtle Beach Inc., a Stripes Group portfolio company and leading provider of headsets for gaming devices like the Xbox, PlayStation,Wii and PC, as well asmobile devices such as tablets and smartphones. In addition, Ron is founder and principal of Erasmus Equity Investments and serves as an advisory board member of Jawfish Games. He is also a member of the board of overseers of Columbia Business School, and a board member of the Prevent Cancer Foundation. His past associations include being an advisor to the board of directors of Activision-Blizzard, member of the board of directors of Activision, president of Activision, chairman and chief executive officer of Activision Publishing, and president of Hunt-Wesson Snack Food, a division of ConAgra Foods. Earlier, he held progressive positions in marketing and general management with Procter & Gamble.Ron lives in Manhattan Beach California, is a dual citizen (USA and the Netherlands) and he is married with four children.

Total investments:
2
Last investment:
Lead investor:
0%

Last updated:

Industries Ron Doornink invests in

VideoComputerHealth CareHealth DiagnosticsInformation Technology

Stages Ron Doornink invests in

Series AConvertible Note

Countries Ron Doornink invests in

Israel

Contacts

TypeContactValidation
Work email
Personal email
Work phone
Personal phone
Socials

Sign up to unlock verified contacts

Unlock Contacts

Investment Focus

Industry

  • Video 1 (50%)
  • Computer 1 (50%)
  • Health Care 1 (50%)
  • Health Diagnostics 1 (50%)
  • Information Technology 1 (50%)

Stage

  • Series A 1 (50%)
  • Convertible Note 1 (50%)

Investments

CompanyDescriptionRoundLinks
Magentiq Eye Ltd. was established in 2014 with the aim to harness the most cutting edge computer vision and deep learning techniques to aid doctors in endoscopic procedures. Doctors today spend hours during Endoscopic Procedures looking at the LCD screens in order to explore, examine and treat various conditions. At Magentiq Eye we put the growingpower of Deep Learning, Image and Video Processing to the help of doctors, so they can be more accurate and effective- ultimately saving millions of lives and billions of dollars. Our first product is APDS: Automatic Polyp Detection System, developed to be used in online and offline colonoscopies. Our APDS (Automatic Polyp Detection System) can point out the suspicious locations of polyps in the videos, increasing the attentiveness of doctors during procedures, thus helping them to reduce their polyp miss-rates. Given the large population that annually undergoes colonoscopy, even a modest decrease in polyp miss-rate can save a lot of lives! The APDS- RT runs on the video feed from the endoscopic camera used by the physician in real time during the endoscopic procedure (currently only on Colonoscopy Procedure). The APDS-OFL is a software that runs in off-line mode on pre-Recorded Colonoscopy Videos. It is estimated that 40 million colonoscopy procedures are performed every year (almost 40% in the US alone). The ability of colonoscopy procedures to decrease the number of colon cancer cases has been proven without a doubt and their number expected to grow. However, researches have shown that there is about 25% of misses (undetected polyps) in those procedures, misses which can, unfortunately, cause interval cancer. Within this context The APDS can be sold as an add-on to the colonoscopy system or as a service (license per exam), paid by the clinic or hospital. Once the APDS system would be formally proven, during the next year, to improve polyp detection rate, it could be sold either jointly with the endoscopic equipment providers or it can be integrated in the colonoscopy devices. Series A / Jul 30, 2025
Magentiq Eye Ltd. was established in 2014 with the aim to harness the most cutting edge computer vision and deep learning techniques to aid doctors in endoscopic procedures. Doctors today spend hours during Endoscopic Procedures looking at the LCD screens in order to explore, examine and treat various conditions. At Magentiq Eye we put the growingpower of Deep Learning, Image and Video Processing to the help of doctors, so they can be more accurate and effective- ultimately saving millions of lives and billions of dollars. Our first product is APDS: Automatic Polyp Detection System, developed to be used in online and offline colonoscopies. Our APDS (Automatic Polyp Detection System) can point out the suspicious locations of polyps in the videos, increasing the attentiveness of doctors during procedures, thus helping them to reduce their polyp miss-rates. Given the large population that annually undergoes colonoscopy, even a modest decrease in polyp miss-rate can save a lot of lives! The APDS- RT runs on the video feed from the endoscopic camera used by the physician in real time during the endoscopic procedure (currently only on Colonoscopy Procedure). The APDS-OFL is a software that runs in off-line mode on pre-Recorded Colonoscopy Videos. It is estimated that 40 million colonoscopy procedures are performed every year (almost 40% in the US alone). The ability of colonoscopy procedures to decrease the number of colon cancer cases has been proven without a doubt and their number expected to grow. However, researches have shown that there is about 25% of misses (undetected polyps) in those procedures, misses which can, unfortunately, cause interval cancer. Within this context The APDS can be sold as an add-on to the colonoscopy system or as a service (license per exam), paid by the clinic or hospital. Once the APDS system would be formally proven, during the next year, to improve polyp detection rate, it could be sold either jointly with the endoscopic equipment providers or it can be integrated in the colonoscopy devices. $600K / Convertible Note / Aug 16, 2022

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Financial Services
Construction
Mobile
Oil and Gas
Retail
Payments
Film
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Social Network
B2B
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Theatre
Beauty
Fashion
Infrastructure
Social
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Medical
Wine and Spirits
Mobile Apps
Real Estate
Web3
Sporting Goods
Music
Art
Finance
Recruiting
Manufacturing
FinTech
Franchise
Social Media
Internet
Mobile Advertising
Android
Impact
Enterprise
Proptech
Hardware
Transportation
Community
Biotech
Sustainability
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
Faroe Islands
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
South Korea
Oman
Puerto Rico
Poland
Guernsey
Cameroon
China
Colombia
Armenia
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Morocco
Australia
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Moldova
New Zealand
Seychelles
Paraguay
Botswana
France
South Africa
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Ron Doornink invest in?

Ron Doornink invests primarily in Video, Computer and Health Care startups, most often at Series A and Convertible Note stage. Most of the 2 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

How do I contact Ron Doornink?

Public channels for Ron Doornink include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

When did Ron Doornink last invest?

The most recent investment recorded for Ron Doornink closed in Jul 2025. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Ron Doornink Ron Doornink Find email